drugset

drugset / Trial / NCT01134835

PPAR-gamma: a Novel Therapeutic Target for Asthma?

NCT01134835 ↗

Phase 4 Terminated 68 enrolled University of Nottingham

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To test the hypothesis that stimulation of PPAR-γ receptors has a therapeutic role in the treatment of asthma.

Timeline

Start: 2010-06
Primary completion: 2012-02
Completion: 2012-07

Outcome

Missed primary endpoint

Stopped: “safety concerns with pioglitazone”

paper There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) PMID 27560168 ↗

Publications

Anderson JR, Mortimer K, Pang L, Smith KM, Bailey H, Hodgson DB, Shaw DE, Knox AJ, Harrison TW. Evaluation of the PPAR-gamma Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. PLoS One. 2016 Aug 25;11(8):e0160257. doi: 10.1371/journal.pone.0160257. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	45 mg	Oral

Indications